{
    "clinical_study": {
        "@rank": "74102", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who\n      have advanced salivary gland cancer that cannot be removed during surgery."
        }, 
        "brief_title": "Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery", 
        "condition": "Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Salivary Gland Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Evaluate the response rate of patients with incurable salivary gland cancer treated\n           with gemcitabine.\n\n        -  Evaluate the time to progression and toxicity of this therapy in these patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive gemcitabine IV for 30 minutes on days 1, 8, and 15 of each 28 day course.\n      Patients receive a minimum of 2 courses of treatment. Patients may continue treatment in the\n      absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 2 months.\n\n      PROJECTED ACCRUAL: This study will accrue a total of 16-60 patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically diagnosed metastatic salivary gland cancer including:\n\n               -  Adenoid cystic carcinoma\n\n               -  Mucoepidermoid carcinoma\n\n               -  Acinic cell carcinoma\n\n               -  Malignant mixed tumor\n\n               -  Polymorphous low grade adenocarcinoma\n\n               -  Undifferentiated carcinoma\n\n               -  Squamous cell carcinoma\n\n               -  Adenocarcinoma\n\n          -  Local or distant metastases\n\n          -  Unresectable tumor\n\n          -  Unidimensionally measurable disease\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  At least 3 months\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 2000/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Hemoglobin greater than 8.5 g/dL OR\n\n          -  Hematocrit greater than 25%\n\n        Hepatic:\n\n          -  Bilirubin less than 2 times upper limit of normal (ULN)\n\n          -  AST less than 2 times ULN (less than 5 times ULN if liver involved)\n\n          -  Alkaline phosphatase less than 5 times ULN (no limit if liver involved)\n\n        Renal:\n\n          -  Creatinine less than 1.5 times ULN OR\n\n          -  Creatinine clearance at least 50% of lower limit of normal\n\n        Cardiovascular:\n\n          -  No congestive heart failure\n\n        Pulmonary:\n\n          -  No chronic obstructive pulmonary disease\n\n        Other:\n\n          -  At least 3 years since prior invasive neoplasm except:\n\n               -  Nonmelanoma skin cancer\n\n               -  Cervical cancer\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  No other significant active illness (e.g., uncontrolled diabetes, AIDS)\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 28 days since prior immunotherapy\n\n          -  No concurrent immunotherapy\n\n        Chemotherapy:\n\n          -  No prior cytotoxic chemotherapy for disease\n\n          -  No other concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  At least 28 days since prior hormone therapy\n\n          -  No concurrent hormone therapy\n\n        Radiotherapy:\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  At least 28 days since prior homeopathic, natural, or alternative therapies\n\n          -  No concurrent homeopathic, natural, or alternative therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003744", 
            "org_study_id": "CDR0000066863", 
            "secondary_id": [
                "DFCI-98168", 
                "LILLY-DFCI-98168", 
                "NCI-G99-1496"
            ]
        }, 
        "intervention": {
            "intervention_name": "gemcitabine hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "keyword": [
            "stage III salivary gland cancer", 
            "stage IV salivary gland cancer", 
            "salivary gland squamous cell carcinoma", 
            "salivary gland acinic cell tumor", 
            "low-grade salivary gland mucoepidermoid carcinoma", 
            "high-grade salivary gland mucoepidermoid carcinoma", 
            "salivary gland adenocarcinoma", 
            "salivary gland poorly differentiated carcinoma", 
            "salivary gland anaplastic carcinoma", 
            "salivary gland malignant mixed cell type tumor", 
            "salivary gland adenoid cystic carcinoma"
        ], 
        "lastchanged_date": "July 23, 2008", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DFCI-98168"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637-1470"
                    }, 
                    "name": "University of Chicago Cancer Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Gemcitabine for Advanced Salivary Cancer: A Phase II Study", 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Marshall R. Posner, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003744"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Dana-Farber Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2004"
    }, 
    "geocoordinates": {
        "Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute": "42.358 -71.06", 
        "Massachusetts General Hospital Cancer Center": "42.358 -71.06", 
        "University of Chicago Cancer Research Center": "41.878 -87.63"
    }
}